Literature DB >> 19174531

Presence of pituitary adenylate cyclase activating polypeptide-38 in human plasma and milk.

Rita Borzsei1, Laszlo Mark, Andrea Tamas, Terez Bagoly, Csaba Bay, Katalin Csanaky, Eszter Banki, Peter Kiss, Alexandra Vaczy, Gabriella Horvath, Jozsef Nemeth, Edit Szauer, Zsuzsanna Helyes, Dora Reglodi.   

Abstract

OBJECTIVE: Pituitary adenylate cyclase activating polypeptide (PACAP) is a pleiotropic and multifunctional neuropeptide widely distributed throughout the body. It is involved in the regulation of various physiological and pathophysiological processes, such as reproduction, thermoregulation, motor activity, brain development, neuronal survival, inflammation and pain. Since little is known about its distribution in humans, our aim was to examine PACAP-38 in human plasma. Furthermore, based on the presence of vasoactive intestinal peptide, structurally the closest to PACAP, in milk and PACAP and its receptors in the mammary gland, our aim was to study PACAP-38 in human milk. DESIGN AND METHODS: The presence of PACAP-38 was determined by mass spectrometry in plasma samples from healthy male and female volunteers (age: 20-40), as well as in plasma and milk samples from lactating women (age: 20-35). PACAP concentration was measured with a specific and sensitive RIA.
RESULTS: Our results revealed that PACAP-38 is present in human plasma, its concentration is relatively stable in healthy volunteers and it is not significantly altered by gender, age, food intake or hormonal cycle in females. However, PACAP-38 plasma levels significantly increased in lactating women having 1-6 month-old babies. Moreover, this study is the first which provides evidence for the presence of PACAP-38 in the human milk with levels 5-20-fold greater in the milk whey than in the respective plasma samples.
CONCLUSIONS: We found PACAP-38 in human plasma and its increase during the first 6 months of the lactation period. A prominent, nearly 10-fold higher concentration of this peptide was detected in human milk. Based on the literature, several important actions of milk-derived PACAP-38 can be suggested such as mammary gland proliferation, nutrient transfer as well as regulation of growth/differentiation of certain tissues of the neonates. The novelty of the present descriptive data provides a basis for further investigations on the mechanism of PACAP-38 secretion in human milk and its functional significance.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19174531     DOI: 10.1530/EJE-08-0911

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  23 in total

1.  PACAP immunoreactivity in human malignant tumor samples and cardiac diseases.

Authors:  Z Szanto; Zs Sarszegi; D Reglodi; J Nemeth; K Szabadfi; P Kiss; A Varga; E Banki; K Csanaky; B Gaszner; O Pinter; Zs Szalai; A Tamas
Journal:  J Mol Neurosci       Date:  2012-05-31       Impact factor: 3.444

2.  Changes in PACAP immunoreactivity in human milk and presence of PAC1 receptor in mammary gland during lactation.

Authors:  Katalin Csanaky; Eszter Banki; Krisztina Szabadfi; Dora Reglodi; Ibolya Tarcai; Levente Czegledi; Zsuzsanna Helyes; Tibor Ertl; Judit Gyarmati; Zalan Szanto; Istvan Zapf; Erika Sipos; Seiji Shioda; Andrea Tamas
Journal:  J Mol Neurosci       Date:  2012-04-27       Impact factor: 3.444

3.  Pituitary adenylate cyclase-activating polypeptide is a potent broad-spectrum antimicrobial peptide: Structure-activity relationships.

Authors:  Charles G Starr; Jerome L Maderdrut; Jing He; David H Coy; William C Wimley
Journal:  Peptides       Date:  2018-04-11       Impact factor: 3.750

4.  Alterations of pituitary adenylate cyclase-activating polypeptide-like immunoreactivity in the human plasma during pregnancy and after birth.

Authors:  D Reglodi; J Gyarmati; T Ertl; R Borzsei; J Bodis; A Tamas; P Kiss; K Csanaky; E Banki; C Bay; J Nemeth; Z Helyes
Journal:  J Endocrinol Invest       Date:  2010 Jul-Aug       Impact factor: 4.256

5.  Regulation of oxidative stress by pituitary adenylate cyclase-activating polypeptide (PACAP) mediated by PACAP receptor.

Authors:  Hirokazu Ohtaki; Atsushi Satoh; Tomoya Nakamachi; Sachiko Yofu; Kenji Dohi; Hiroyoshi Mori; Kenji Ohara; Kazuyuki Miyamoto; Hitoshi Hashimoto; Norihito Shintani; Akemichi Baba; Masaji Matsunaga; Seiji Shioda
Journal:  J Mol Neurosci       Date:  2010-04-13       Impact factor: 3.444

Review 6.  PACAP: A regulator of mammalian reproductive function.

Authors:  Stephen J Winters; Joseph P Moore
Journal:  Mol Cell Endocrinol       Date:  2020-06-17       Impact factor: 4.102

7.  Pituitary adenylate cyclase-activating polypeptide (PACAP) signalling enhances osteogenesis in UMR-106 cell line.

Authors:  Tamás Juhász; Csaba Matta; Éva Katona; Csilla Somogyi; Roland Takács; Tibor Hajdú; Solveig Lind Helgadottir; János Fodor; László Csernoch; Gábor Tóth; Éva Bakó; Dóra Reglődi; Andrea Tamás; Róza Zákány
Journal:  J Mol Neurosci       Date:  2014-08-12       Impact factor: 3.444

8.  Effects of pituitary adenylate cyclase activating polypeptide on human sperm motility.

Authors:  R Brubel; P Kiss; A Vincze; A Varga; A Varnagy; J Bodis; L Mark; E Jambor; G Maasz; H Hashimoto; Zs Helyes; G Toth; A Tamas; M Koppan; D Reglodi
Journal:  J Mol Neurosci       Date:  2012-05-26       Impact factor: 3.444

9.  Influence of terminal differentiation and PACAP on the cytokine, chemokine, and growth factor secretion of mammary epithelial cells.

Authors:  Katalin Csanaky; Wolfgang Doppler; Andrea Tamas; Krisztina Kovacs; Gabor Toth; Dora Reglodi
Journal:  J Mol Neurosci       Date:  2013-12-10       Impact factor: 3.444

Review 10.  CGRP and migraine: could PACAP play a role too?

Authors:  Eric A Kaiser; Andrew F Russo
Journal:  Neuropeptides       Date:  2013-10-23       Impact factor: 3.286

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.